Strata Critical Medical, Inc. (SRTA)
NASDAQ:SRTA
Want to see SRTA full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a broadly positive tone driven by very strong year-over-year revenue (+87.4%), doubled gross profit, rapid build-out and commercial traction in the Clinical business, healthy cash on hand and an active M&A pipeline. Offsetting these positives were sequential softness in Logistics revenue and margins (customer mix and weather-related disruptions), a sequential decline in adjusted EBITDA margin, some one-time cash timing effects, and ongoing uncertainty in donor volumes. Management reiterated full-year guidance and highlighted balance sheet capacity, suggesting confidence in execution despite near-term noise.Company Guidance
Revenue Growth
Total revenue increased 87.4% year-over-year to $67.4M in Q1 2026 (from $35.9M) and was up ~1% sequentially versus Q4 2025; performance was reported as ahead of guidance for both revenue and adjusted EBITDA.
Strong Organic Logistics Growth
Logistics (organic, excluding Keystone) revenue rose 32.4% year-over-year to $47.6M, driven primarily by higher Air revenue from new and existing customers.
Rapid Build-Out of Clinical Business
Clinical revenue (new after Keystone) reached $19.8M in Q1 2026, up 12.7% sequentially vs Q4 2025; Transplant Clinical revenue rose 26.7% sequentially and Other Clinical also increased, reflecting cross-sell wins and new customer onboarding.
Profitability and Margins Improvement Year-over-Year
Gross profit doubled (+100%) to $14.1M versus prior year ($7.1M) and gross margin improved ~140 basis points year-over-year to 21.0% (from 19.6%), aided by the Keystone acquisition mix.
Clinical Margin Strength
Clinical gross profit rose 29.2% sequentially to $5.0M and clinical gross margin improved to 25.0% from 21.8% sequentially as mix shifted toward transplant clinical services.
Cash Generation and Balance Sheet Capacity
Operating cash flow was $3.9M and free cash flow before aircraft/engine acquisitions was $2.1M in Q1; cash and short-term investments totaled $58.8M, with an undrawn $30M ABL (upsizable to $50M) and expected earn-outs (~$45M) providing M&A capacity.
M&A Activity and Pipeline
Closed acquisition of Ohio Valley Perfusion Associates (~$1M purchase, expected to contribute ~$100k adjusted EBITDA for the remainder of 2026) and an active pipeline including several exclusivity deals across logistics, surgical recovery, placement and cardiac perfusion.
Fleet and Geographic Expansion
Acquired 1 aircraft (10 owned aircraft total; dedicated fleet ~35), opened several new aviation bases, grew to ~20 logistics hubs and launched a combined Logistics & Clinical hub in Chicago to serve the Midwest.
Industry Tailwinds and Market Position
Company highlighted increased adoption of NRP (>50% of DCD donors), greater use of third-party surgical recovery, and sequential improvement in deceased donor volumes since Q4 2025—trends that support demand for Strata’s integrated clinical and logistics platform.
Reiterated Full-Year Guidance
Management reiterated 2026 guidance: revenue $260M–$275M, adjusted EBITDA $29M–$33M, and free cash flow before aircraft/engine purchases $15M–$22M, signaling confidence in FY outlook.
SRTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SRTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $4.82 | $5.33 | +10.58% |
Mar 03, 2026 | $4.49 | $4.80 | +6.90% |
Nov 10, 2025 | $4.43 | $4.85 | +9.48% |
Aug 05, 2025 | $4.43 | $4.16 | -6.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Strata Critical Medical, Inc. (SRTA) report earnings?
Strata Critical Medical, Inc. (SRTA) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Strata Critical Medical, Inc. (SRTA) earnings time?
Strata Critical Medical, Inc. (SRTA) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRTA EPS forecast?
SRTA EPS forecast for the fiscal quarter 2026 (Q2) is -0.03.